Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

BACKGROUND: The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This biomarker analysis of the DAWN dataset sought to determine gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasubramanian, Sriram, Hodkinson, Brendan, Schuster, Stephen J., Fowler, Nathan H., Trotman, Judith, Hess, Georg, Cheson, Bruce D., Schaffer, Michael, Sun, Steven, Deshpande, Sanjay, Vermeulen, Jessica, Salles, Gilles, Gopal, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704158/
https://www.ncbi.nlm.nih.gov/pubmed/34791836
http://dx.doi.org/10.1002/cam4.4422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704158/
https://www.ncbi.nlm.nih.gov/pubmed/34791836
http://dx.doi.org/10.1002/cam4.4422

Ejemplares similares